BridgeBio Pharma Inc (NASDAQ: BBIO) closed the day trading at $35.73 up 2.47% from the previous closing price of $34.87. In other words, the price has increased by $+0.86 from its previous closing price. On the day, 1308654 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of BBIO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on January 31, 2024, initiated with a Market Perform rating and assigned the stock a target price of $37.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $58.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 when Valantine Hannah sold 2,915 shares for $37.75 per share. The transaction valued at 110,041 led to the insider holds 1,764 shares of the business.
Valantine Hannah sold 2,915 shares of BBIO for $110,683 on Jan 16. The Director now owns 1,764 shares after completing the transaction at $37.97 per share. On Dec 26, another insider, MCCORMICK FRANK, who serves as the Director of the company, sold 100,000 shares for $42.06 each. As a result, the insider received 4,206,000 and left with 627,689 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 6.28B and an Enterprise Value of 7.59B. For the stock, the TTM Price-to-Sale (P/S) ratio is 675.53. Its current Enterprise Value per Revenue stands at 815.59 whereas that against EBITDA is -13.42.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $44.32, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 37.07, while the 200-Day Moving Average is calculated to be 28.01.
Shares Statistics:
Over the past 3-months, BBIO traded about 1.82M shares per day on average, while over the past 10 days, BBIO traded about 1.7M shares per day. A total of 175.08M shares are outstanding, with a floating share count of 129.58M. Insiders hold about 26.31% of the company’s shares, while institutions hold 74.82% stake in the company. Shares short for BBIO as of Jan 31, 2024 were 14.21M with a Short Ratio of 7.79, compared to 17.08M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.17% and a Short% of Float of 13.32%.
Earnings Estimates
Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$0.91 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$1.18, while EPS last year was -$0.92. The consensus estimate for the next quarter is -$1, with high estimates of -$0.79 and low estimates of -$1.27.
Analysts are recommending an EPS of between -$1.76 and -$5.05 for the fiscal current year, implying an average EPS of -$3.68. EPS for the following year is -$3.21, with 10 analysts recommending between -$2.42 and -$4.85.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $459.78M, while the lowest revenue estimate was $7.1M, resulting in an average revenue estimate of $73.11M. In the same quarter a year ago, actual revenue was $9.3M, up 685.90% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $275.59M in the next fiscal year. The high estimate is $1.14B and the low estimate is $61.3M. The average revenue growth estimate for next year is up 277.00% from the average revenue estimate for this year.
